Calquence (Acalabrutinib)
- Medicine Name: Calquence
- Generic Name: Acalabrutinib
- Dosage Form & Strength: Capsules: 100 mg
- Manufactured By: AstraZeneca Pharma
Medical Uses
Calquence is a kinase inhibitor used for the treatment of adult patients with:
Mantle cell lymphoma (MCL) who have previously received at least one therapy.
- Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL).
Recommended Dosage: For those with MCL, CLL, or SLL, the recommended dose of Calquence as Monotherapy is 100 mg taken by mouth approximately every 12 hours until the disease is progressive or unacceptable toxicity occurs.
For those with previously untreated CLL or SLL, the recommended dose of Calquence in Combination with Obinutuzumab is 100 mg taken by mouth approximately every 12 hours until the disease is progressive or unacceptable toxicity occurs. Initiate treatment at Cycle 1 (1 cycle = 28 days). Initiate obinutuzumab at Cycle 2 for a total of six cycles. The medication Calquence should be administered prior to obinutuzumab when given on the same day.
Do not open, break or chew the capsules but swallow as whole with water. Do not chew, crush, dissolve, or cut the Calquence tablets. Take dosage with or without food. In case a dose is missed by more than three hours, it should be skipped and the very next dose should be taken at its regularly scheduled time. It is not advisable to take extra capsules to make up for a missed dose.
Warning & Precautions
- Fatal and severe infections, including opportunistic infections, may occur in those with hematologic malignancies treated with Acalabrutinib. Consider prophylaxis in those who are at higher risk for opportunistic infections. Evaluate patients for signs/symptoms of infection and treat them as soon as possible.
- Fatal and severe hemorrhagic events may occur in those with hematologic malignancies treated with calquence 100 mg. Use of antithrombotic agents concomitantly with this medication may further increase the probability of hemorrhage. Evaluate patients for signs of bleeding.
- Grade 3/4 cytopenias, including neutropenia, anemia, thrombocytopenia, and lymphopenia, may develop in those with hematologic malignancies treated with Acalabrutinib. Monitor complete blood counts (CBCs) regularly throughout the therapy. Interrupt therapy, reduce the dose, or discontinue therapy as warranted.
- Second primary malignancies, including skin cancers and other solid tumors may occur in those exposed to Acalabrutinib. The most frequent second primary malignancy is skin cancer. Monitor patients for skin cancers and protection from sun exposure is required.
- Grade 3 atrial fibrillation or flutter may occur in those treated with Acalabrutinib, with all grades of atrial fibrillation or flutter may be reported in patients. Risk may be increased in those with hypertension, cardiac risk factors, acute infection and previous arrhythmias. Monitor for signs and symptoms of arrhythmia (e.g., dizziness, syncope, palpitations, dyspnea) and manage as required.
- Based on findings, acalabrutinib dose may cause fetal harm and dystocia is used by a pregnant woman. Female patients of reproductive age should use effective contraception during therapy with acalabrutinib and for at least 7 days after the last dose. Pregnancy testing is recommended for females of reproductive age before initiating acalabrutinib therapy.
- Females should not breastfeed during therapy with acalabrutinib and for at least 2 weeks after the last dose. Avoid the use of acalabrutinib in those with severe hepatic impairment. The safety of acalabrutinib has not been assessed in thode with moderate or severe hepatic impairment. Safety as well as efficacy in pediatric patients have not been established.
Documentation & Availability
What documents are required to import CALQUENCE to India?
CALQUENCE (acalabrutinib) capsules/tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is CALQUENCE available in India?
CALQUENCE (acalabrutinib capsules/tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Calquence in India (Mumbai, Pune, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, and Bangalore etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
CALQUENCE can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of CALQUENCE (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Calquence 100 mg price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
Indian Pharma Network is able to source the CALQUENCE (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Calquence®?
Acalabrutinib is Generic Name for the trade name drug Calquence®.
What is the Manufacturer Name of Calquence®?
Calquence® is manufactured by AstraZeneca Pharmaceuticals LP.
Is Calquence® approved by the FDA?
Yes, Calquence® is approved by the FDA. Date of approval: January 2017.
What is the dosage and form of Calquence® supplied?
Calquence® is supplied as Capsules: 100 mg for oral administration.
Where can I get Calquence® at the best price in India?
To get the best Calquence price in India, please contact Indian Pharma Network (a WHO-GDP and ISO 9001:2008 authorized Company). A medical prescription is required while buying Calquence®.
What are the most common side effects with Calquence®?
The most common side effects with Calquence® are: headache, anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, musculoskeletal pain and diarrhea.
How much does Calquence® cost in India?
Calquence® acalabrutinib cost in India is less and can vary. In order to buy/procure this medication authentically, you can Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Calquence®?
Store Calquence capsules/tablets at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).
Is it safe to buy Calquence® online from India?
Yes, You can buy Calquence online in India at the best price from the Indian Pharma Network (IPN) if Calquence® has not been approved or is not available in your country.
What are the Highlights of prescribing information for Calquence®?
Click Here to download full Calquence prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
